Journal of Neural Transmission

, Volume 111, Issue 2, pp 113–126

Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile

Authors

  • G. D. Bartoszyk
    • Department of CNS-ResearchMerck KGaA
  • C. van Amsterdam
    • Department of CNS-ResearchMerck KGaA
  • H. E. Greiner
    • Department of CNS-ResearchMerck KGaA
  • W. Rautenberg
    • Department of CNS-ResearchMerck KGaA
  • H. Russ
    • Department of Clinical ResearchMerck KGaA
  • C. A. Seyfried
    • Department of CNS-ResearchMerck KGaA
Article

DOI: 10.1007/s00702-003-0094-7

Cite this article as:
Bartoszyk, G., van Amsterdam, C., Greiner, H. et al. J Neural Transm (2004) 111: 113. doi:10.1007/s00702-003-0094-7

Summary.

Sarizotan exhibited high affinities only to serotonin 5-HT1A receptors and dopamine DA D4>D3>D2 receptors with the profile of a 5-HT1A agonist and DA antagonist demonstrated by the inhibition of cAMP-stimulation and guinea pig ileum contraction, decreased accumulation of the 5-HT precursor 5-hydroxytryptophan and increased levels of 5-HT metabolites, increased accumulation of DA precursor dihydroxyphenylalanine (DOPA) and the reduced levels of DA metabolites in intact rats. However, sarizotan at higher doses decreased DA precursor accumulation in reserpinized rats and induced contralateral rotational behavior in unilaterally substantia nigra lesioned rats, indicating some intrinsic dopaminergic activity; at D2 receptors sarizotan may act as a partial agonist, depending on the dopaminergic impulse flow. Sarizotan represents a new approach for the treatment of extrapyramidal motor complications such as l-DOPA-induced dyskinesia in Parkinson’s disease.

Keywords: Sarizotan, serotonin 5HT1A agonist, dopamine ligand, dyskinesia, Parkinson’s disease, neurotransmitter turnover, extrapyramidal movement disorders
Download to read the full article text

Copyright information

© Springer-Verlag/Wien 2003